Skip to main content

Table 1 Baseline characteristics of patients with ypT0-3N0 rectal cancer

From: Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery

   Before matching After matching
Overall n = 339 (%) No AC n = 87 (%) AC n = 252 (%) p-value No AC n = 87 (%) AC n = 87 (%) p-value
Median age (range), years 59.6 (27.2–85.7) 65.9 (36.0–85.7) 58.3 (27.2–84.6) <0.001 65.9 (36.0–85.7) 63.7 (39.1–84.6) 0.251
Sex     0.752    0.602
 Male 246 (72.6) 62 (71.3) 184 (73.0)   62 (71.3) 59 (67.8)  
 Female 93 (27.4) 25 (28.7) 68 (27.0)   25 (28.7) 28 (32.2)  
Distance from AV (cm)        0.342
 ≥ 10.0 35 (10.3) 8 (9.2) 27 (10.7)   8 (9.2) 9 (10.3)  
 5.0–9.9 140 (41.3) 33 (37.9) 107 (42.5)   33 (37.9) 40 (46.0)  
 < 5.0 164 (48.4) 46 (52.9) 118 (46.8)   46 (52.9) 38 (43.7)  
Differentiation     0.176    0.300
 Well 70 (20.6) 17 (19.5) 53 (21.0)   17 (19.5) 20 (23.0)  
 Moderate 248 (73.2) 61 (70.1) 187 (74.2)   61 (70.1) 62 (71.3)  
 Poor, mucinous 21 (6.2) 9 (10.3) 12 (4.8)   9 (10.3) 5 (5.7)  
Pretreatment CEA (ng/mL)     0.621    0.413
 < 5 214 (63.1) 53 (60.9) 161 (63.9)   53 (60.9) 58 (66.7)  
 ≥ 5 125 (36.9) 34 (39.1) 91 (36.1)   34 (39.1) 29 (33.3)  
Surgical procedure     0.573    0.350
 LAR 298 (87.9) 75 (86.2) 232 (88.5)   75 (86.2) 79 (90.8)  
 APR 41 (12.1) 12 (13.8) 29 (11.5)   12 (13.8) 8 (9.2)  
Stage     <0.001    0.383
 ypT0 90 (26.5) 40 (46.0) 50 (19.8)   40 (46.0) 37 (42.5)  
 ypT1 19 (5.6) 6 (6.9) 13 (5.2)   6 (6.9) 4 (4.6)  
 ypT2 96 (28.3) 25 (28.7) 71 (28.2)   25 (28.7) 26 (29.9)  
 ypT3 134 (39.5) 16 (18.4) 118 (46.8)   16 (18.4) 20 (23.0)  
LN dissected     0.146    0.538
 < 12 145 (42.8) 43 (49.4) 102 (40.5)   43 (49.4) 39 (44.8)  
 ≥ 12 194 (57.2) 44 (50.6) 150 (59.5)   44 (50.6) 48 (55.2)  
LVI/PNI     0.812    0.657
 Negative 278 (82.0) 71 (81.6) 207 (82.1)   71 (81.6) 80 (92.0)  
 Positive 15 (4.4) 3 (3.4) 12 (4.8)   3 (3.5) 2 (2.3)  
 NA 46 (13.6) 13 (14.9) 33 (13.1)   13 (14.9) 5 (5.8)  
Margin     0.677    1.000
 Negative 329 (97.1) 85 (97.7) 244 (96.8)   85 (97.7) 85 (97.7)  
 Positive 10 (2.9) 2 (2.3) 8 (3.2)   2 (2.3) 2 (2.3)  
Mandard regression grade     <0.001    0.926
 Grade 1 90 (26.5) 40 (46.0) 50 (19.8)   40 (46.0) 37 (42.5)  
 Grade 2 90 (26.5) 17 (19.5) 73 (29.0)   17 (19.5) 22 (25.3)  
 Grade 3 78 (23.0) 11 (12.6) 67 (26.6)   11 (12.6) 15 (17.2)  
 Grade 4 36 (10.6) 6 (6.9) 30 (11.9)   6 (6.9) 8 (9.2)  
 NA 45 (13.3) 13 (14.9) 32 (12.7)   13 (14.9) 5 (5.8)  
  1. AC adjuvant chemotherapy, AV anal verge, CEA carcinoembryonic antigen, LAR lower anterior resection, APR abdomino-perineal resection, LN lymph node, LVI lymphovascular invasion, PNI perineural invasion, NA not assessed